Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

PD-L1 antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) Antibody-Drug Conjugates (ADCs) (3) PD-1/PD-L1 (122) Apoptosis (6) Autophagy (1) CD19 (1) CD3 (3) CD47 (3) Collagen (1) COX (1) CTLA-4 (6) DNA-PK (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (1) EGFR (2) Fluorescent Dye (1) HSP (1) IFNAR (4) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (1) Interleukin Related (4) LAG-3 (1) Liposome (1) MAP4K (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) MMP (2) PERK (1) Phosphodiesterase (PDE) (1) PROTACs (1) Ras (1) ROR (1) Scavenger Receptor Class B type I (SR-BI） (1) SHP1 (1) STAT (1) STING (1) TGF-beta/Smad (2) Tim3 (2) TNF Receptor (6) Toll-like Receptor (TLR) (6) Transmembrane Glycoprotein (5) VEGFR (8)
By Research Areas:	Cancer (126) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (47) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	Labeling and Fluorescence Imaging (1) Azide (1)
Oligonucleotides:	CpG ODNs (1) Cationic Lipids (1)

138

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

120

Inhibitory Antibodies

Antibodies

Click Chemistry

Oligonucleotides

Atezolizumab Maximum Cited Publications 36 Publications Verification MPDL3280A; RG-7446; RO-5541267	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Pembrolizumab 25+ Cited Publications MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Nivolumab 20+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Infection Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Durvalumab 5+ Cited Publications MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

Anti-Mouse PD-1 Antibody (RMP1-14) 20+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse *PD-1* IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma .

Avelumab 5+ Cited Publications Anti-Human PD-L1, Human antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .

*Anti-Mouse PD-L1/B7-H1 Antibody* (10F.9G2)** 10+ Cited Publications	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse *PD-L1/B7-H1* IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .

Pembrolizumab (anti-PD-1) 5 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

Rosnilimab ANB030	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (ANB030) is a *PD-1* agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high *PD-1* expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .

Durvalumab (anti-PD-L1) 5+ Cited Publications MEDI 4736 (anti-PD-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity .

Toripalimab JS-001	PD-1/PD-L1	Cancer
Toripalimab is a selective, recombinant, humanized monoclonal antibody against *PD-1. Toripalimab is able to bind to PD-1* and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting *PD-L1* and VEGF-A, with immune activation and anti-angiogenic activities. By binding to *PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A* in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HLX43	Antibody-Drug Conjugates (ADCs) PD-1/PD-L1	Cancer
HLX43 is an antibody-drug conjugate (ADC) targeting *PD-L1. HLX43 consists of a human monoclonal antibody* anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .

Tislelizumab 3 Publications Verification BGB-A317	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1. Anti-Mouse PD-1* Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived *PD-L1* IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer .

SSGJ-707 PF-08634404	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and *PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1* signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by *PD-L1* expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .

Sulfo-Cy5 azide	Fluorescent Dye PD-1/PD-L1	Inflammation/Immunology Cancer
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of *PD-L1* in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) .

PF-08046054 SGN-PDL1V	Antibody-Drug Conjugates (ADCs) PD-1/PD-L1	Cancer
PF-08046054 (SGN-PDL1V) is a *PD-L1*-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal *PD-L1* (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting *PD-L1* and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology Cancer
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against *PD-1* .

Fetrastobart SGN-PDL1V antibody; PF-08046054 antibody	ADC Antibody	Cancer
SGN-PDL1V Antibody is a *PD-L1* targeting antibody. SGN-PDL1V Antibody can be used for synthesis of ADC SGN-PDL1V (HY-171821) .

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

*Anti-Canine PD-L1/B7-H1 Antibody* (JC071)**	PD-1/PD-L1	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine *PD-L1/B7-H1* IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .

Peresolimab 1 Publications Verification LY-3462817	PD-1/PD-L1	Inflammation/Immunology
Peresolimab is a humanized IgG1-κ antibody targeting to *PD-1*. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis .

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

AXC-715 hydrochloride T785 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist. AXC-715 can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

Erfonrilimab KN-046	PD-1/PD-L1 CTLA-4	Cancer
Erfonrilimab (KN-046) is a monoclonal antibody targeting *PD-L1/CTLA-4*. Erfonrilimab blocks the *PD-L1* and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.

Cemiplimab REGN-2810; SAR-439684	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

*Anti-Mouse PD-L1/B7-H1 Antibody* (10F.9G2-Mouse IgG1)**	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) contains no Fc mutations just as the original rat IgG2b antibody does not. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) can be used for the research of cancer.

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer .

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against *CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3* and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or *PD-L1* on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .

Safimestomig 6MW3211	CD47 PD-1/PD-L1	Cancer
Safimestomig (6MW3211) is an *CD47/PD-L1*-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer .

Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

Reozalimab LY3434172; IBI-318	PD-1/PD-L1	Cancer
Reozalimab is a bispecific antibody targeting to *PD-1/PD-L1. Reozalimab mediates antibody*-dependent cell cytotoxicity in cancer research .

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. Gilvetmab blocks the interaction between PD-1 and its ligand PD-L1/L2. Gilvetmab can be used in malignant melanoma and mast cell tumor research .

Enristomig ES-101; INBRX-105	TNF Receptor PD-1/PD-L1	Inflammation/Immunology Cancer
Enristomig (ES-101) is a multispecific antibody. Enristomig is both a *PD-L1* antagonist and a conditional agonist of 4-1BB. Enristomig can be used for research on PD-L1 expressing tumors .

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

783 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 783 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	Product Name	Type

HY-145746

Sulfo-Cy5 azide

Fluorescent Dyes

Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) .

HY-171821

PF-08046054 SGN-PDL1V	Fluorescent Dyes
PF-08046054 (SGN-PDL1V) is a *PD-L1*-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors

Cat. No.	Product Name	Target	Research Area

HY-P5276

Human membrane-bound PD-L1 polypeptide	PD-1/PD-L1	Cancer
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce *PD-L1* antibody production .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9904

Atezolizumab Maximum Cited Publications 36 Publications Verification MPDL3280A; RG-7446; RO-5541267	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P9902

Pembrolizumab 25+ Cited Publications MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P9903

Nivolumab 20+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Infection Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P9919

Durvalumab 5+ Cited Publications MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14) 20+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse *PD-1* IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma .

HY-108730

Avelumab 5+ Cited Publications Anti-Human PD-L1, Human antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .

HY-P99145

*Anti-Mouse PD-L1/B7-H1 Antibody* (10F.9G2)** 10+ Cited Publications	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse *PD-L1/B7-H1* IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .

HY-P9902A

Pembrolizumab (anti-PD-1) 5 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (ANB030) is a *PD-1* agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high *PD-1* expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .

HY-108730A

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .

HY-P9919A

Durvalumab (anti-PD-L1) 5+ Cited Publications MEDI 4736 (anti-PD-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity .

HY-P9978

Toripalimab JS-001	PD-1/PD-L1	Cancer
Toripalimab is a selective, recombinant, humanized monoclonal antibody against *PD-1. Toripalimab is able to bind to PD-1* and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting *PD-L1* and VEGF-A, with immune activation and anti-angiogenic activities. By binding to *PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A* in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HY-P99052

Tislelizumab 3 Publications Verification BGB-A317	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1. Anti-Mouse PD-1* Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

HY-P990173

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived *PD-L1* IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer .

HY-P991628

SSGJ-707 PF-08634404	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and *PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1* signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by *PD-L1* expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal *PD-L1* (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting *PD-L1* and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .

HY-P99457

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology Cancer
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against *PD-1* .

HY-P991506

Fetrastobart SGN-PDL1V antibody; PF-08046054 antibody	ADC Antibody	Cancer
SGN-PDL1V Antibody is a *PD-L1* targeting antibody. SGN-PDL1V Antibody can be used for synthesis of ADC SGN-PDL1V (HY-171821) .

HY-P99166

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P990114

*Anti-Canine PD-L1/B7-H1 Antibody* (JC071)**	PD-1/PD-L1	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine *PD-L1/B7-H1* IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .

HY-P9993

Peresolimab 1 Publications Verification LY-3462817	PD-1/PD-L1	Inflammation/Immunology
Peresolimab is a humanized IgG1-κ antibody targeting to *PD-1*. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis .

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Cancer
Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a K_a of 3.55e-10 M for human Her2 and a K_a of 1.17e-9 M for human *PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2*-positive gastric cancer .

HY-P99345

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99943

Erfonrilimab KN-046	PD-1/PD-L1 CTLA-4	Cancer
Erfonrilimab (KN-046) is a monoclonal antibody targeting *PD-L1/CTLA-4*. Erfonrilimab blocks the *PD-L1* and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.

HY-P99203

Cemiplimab REGN-2810; SAR-439684	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

HY-P990169

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can detect the phosphorylated form of the PD-1 ITSM by both western blot and flow cytometry .

HY-P99145A

*Anti-Mouse PD-L1/B7-H1 Antibody* (10F.9G2-Mouse IgG1)**	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) contains no Fc mutations just as the original rat IgG2b antibody does not. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) can be used for the research of cancer.

HY-P990824

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against *CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3* and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or *PD-L1* on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .

HY-P991023

Safimestomig 6MW3211	CD47 PD-1/PD-L1	Cancer
Safimestomig (6MW3211) is an *CD47/PD-L1*-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer .

HY-P991078

Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P9996

Reozalimab LY3434172; IBI-318	PD-1/PD-L1	Cancer
Reozalimab is a bispecific antibody targeting to *PD-1/PD-L1. Reozalimab mediates antibody*-dependent cell cytotoxicity in cancer research .

HY-P99641

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. Gilvetmab blocks the interaction between PD-1 and its ligand PD-L1/L2. Gilvetmab can be used in malignant melanoma and mast cell tumor research .

HY-P99785

Opucolimab HLX20; HLX43 antibody	PD-1/PD-L1 ADC Antibody	Cancer
Opucolimab (HLX20) is an engineered anti-PD-L1 humanised IgG1 antibody. Opucolimab, when conjugated with camptothecin toxoid, yields the PD-L1-targeting ADC, HLX43 (HY-177439). HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

HY-P991740

IBI-363	PD-1/PD-L1 Interleukin Related	Cancer
IBI-363 is a PD-1/IL-2 bispecific antibody with functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI-363 retains affinity for IL-2Rα but attenuates binding ability to IL-2Rβ and IL-2Rγ to reduce toxicity. The PD-1 binding arm of IBI-363 enables PD-1 blockade and selective delivery of IL-2. IBI-363 can be used in cancer research, such as non-small cell lung cancer .

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block *PD-1* and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with *PD-L1/PD-L2*, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .

HY-P990738

Enristomig ES-101; INBRX-105	TNF Receptor PD-1/PD-L1	Inflammation/Immunology Cancer
Enristomig (ES-101) is a multispecific antibody. Enristomig is both a *PD-L1* antagonist and a conditional agonist of 4-1BB. Enristomig can be used for research on PD-L1 expressing tumors .

Host:	Mouse (6) Rabbit (4)
Reactivity:	Human (9) Mouse (1)
Application:	IHC-P (5) ICC/IF (1) mIHC (1) IF-Tissue (1) IHC-F (1) WB (4) FC (6) ELISA (2)
Isotype:	IgG (6) IgG2b (3)
Conjugation:	APC (1) PE (1) Non-conjugated (8)
Clonality:	YA9804 (1) Monoclonal (7) Recombinant (2)
Modification:	Unmodified (8)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80273

	PD-L1 Antibody (YA235)	WB, IHC-P	Human
	PD-L1 Antibody (YA235) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P84842

	PD-L1 Antibody (YA4539) B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274	IHC-P, FC, ELISA	Human
	PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

HY-P84842A

	PD-L1 Antibody (YA4539)(PBS only) B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274	IHC-P, FC, ELISA	Human
	PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

HY-P87006

	PD-L1 Antibody (YA6699) B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD-274 antibody; CD274 antibody; CD274 antigen antibody; B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD-274 antibody; CD274 antibody; CD274 antigen antibody; CD274 molecule antibody; MGC142294 antibody; MGC142296 antibody; OTTHUMP00000021029 antibody; PD L1 antibody; PD-L1 antibody; PD1L1_HUMAN antibody; PDCD1 ligand 1 antibody; PDCD1L1 antibody; PDCD1LG1 antibody; PDL 1 antibody; PDL1 antibody; Programmed cell death 1 ligand 1 antibody; Programmed death ligand 1 antibody; RGD1566211 antibody;	WB, IHC-P, mIHC	Mouse
	PD-L1 Antibody (YA6699) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P84982

	PD-L1 Antibody (YA4674) 1 Publications Verification Programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD antigen CD274; CD274 nanobody; PD-L1 nanobody;	WB	Human
	PD-L1 Antibody (YA4674) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P810534-APC

	*CD274/PD-L1* Antibody (APC) (YA9804）** CD274/PD-L1	FC	Human

HY-P86684

	PD-L1 Antibody (YA6376) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	WB, IHC-P, IHC-F, IF-Tissue, ICC/IF	Human
	PD-L1 Antibody (YA6376) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P86751

	PD-L1 Antibody (YA6443) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P86751A

	PD-L1 Antibody (YA6443)(PBS only) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P89400M

	*CD274/PD-L1* Antibody (PE) (YA8851)** Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-145746

Sulfo-Cy5 azide		Azide Labeling and Fluorescence Imaging
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of *PD-L1* in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) .

Cat. No.	Product Name		Classification

HY-148511

Vidutolimod CMP-001		CpG ODNs
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, *PDL1, IDO* and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .

HY-169480

Lipid C2		Cationic Lipids
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: